research Les Visiteurs des malades
5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
Search
for
Sort by
Research
510-540 / 1000+ resultsresearch Study the 5α-reductase Inhibitory Activity of Urtica fissa E. Pritz's Extract
Urtica fissa extract can inhibit 5α-reductase activity.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research Inhibitory Effect of Extract of Urtical Mairei Levl on 5α-Reductase Activity
The root extract of Untica mairei Levl may help treat benign prostatic hyperplasia.
research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Synthesis of novel andostane-N-cyclohexyl-17-carboxamides, and their effect on the 5α-reductase isoform 2, the androgen receptor, and androgen-dependent glands
New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
research Finasteride with Doxazosin to Reduce BPH Progression
research Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line‐field confocal optical coherence tomography evaluation
Baricitinib helps with early hair regrowth in people with alopecia areata.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
research Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids
Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild‐type and BK5.AktWT mice
Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.
research 5-Fluorouracil induces hair loss by inhibiting β-catenin signaling and angiogenesis
5-Fluorouracil causes hair loss by blocking signals needed for hair growth.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research 5α-reductase activity in the prostate
Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
research Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate: An In Vitro and In Silico Approach
Phytosterols may help manage prostate issues but are less effective than synthetic drugs.
research Інгібітор 5α-редуктази дутастерид при лікуванні доброякісної гіперплазії передміхурової залози: системний огляд та мета-аналіз
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.